RSC Advances



CORRECTION

View Article Online



Cite this: RSC Adv., 2024, 14, 25077

Correction: Study on mechanism of elemene reversing tumor multidrug resistance based on luminescence pharmacokinetics in tumor cells in vitro and in vivo

Liying Chen, a Zhi Chen, a Shuang Zheng, a Luhui Fan, a Lixin Zhu, ac Jiandong Yu, a Chaoyuan Tang,^a Qi Liu^d and Yang Xiong*^a

DOI: 10.1039/d4ra90085e

rsc.li/rsc-advances

Correction for 'Study on mechanism of elemene reversing tumor multidrug resistance based on luminescence pharmacokinetics in tumor cells in vitro and in vivo' by Liying Chen et al., RSC Adv., 2020, 10, 34928-34937, https://doi.org/10.1039/d0ra00184h.

The authors regret that due to an image selection and processing error, the panel of group B-53 min and group C-93 min were incorrect in Fig. 4. The corrected version of Fig. 4 is provided below:

Department of Pharmaceutical Science, College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 311400, Zhejiang, China

^bThe First People's Hospital of Jiande, Jiande 311600, Zhejiang, China

^eZhejiang Institute for Food and Drug Control, Hangzhou 310004, Zhejiang, China

^dDepartment of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA




Fig. 4 BLI of MCF-7/DOX^{Fluc} tumor-bearing nude mice at different time points within 115 min after intraperitoneal injected D-luc with a dose of 100 mg kg $^{-1}$ (n = 3). (A) PBS group (i.p., QD). (B) The low ELE concentration group (ELE 10 mg kg $^{-1}$, i.p., QD). (C) The high ELE concentration group (ELE 25 mg kg^{-1} , i.p., QD).

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.